Jaguar Animal Health Makes Board of Directors Appointment
Jaguar Animal Health, a pharmaceutical company that makes gastrointestinal medicines for companion and production animals, has appointed industry expert Folkert Kamphuis to its board of directors.
Kamphuis has a long and storied career in the animal health field, including his most recent appointment as global head of strategic planning at Novartis Animal Health, the former animal health division of Swiss pharmaceutical giant Novartis.
At Novartis Kamphuis oversaw business development and licensing, portfolio and sales force development and served on the company's Animal Health Executive Committee.
Prior to joining Novartis in 2009, Kamphuis spent 20 years serving in various roles at Pfizer Animal Health/Pharmacia and at Merial.
San Francisco-based Jaguar makes Canalevia, a prescription drug used to treat severe diarrhea in dogs, and Neonorm Calf, a non-prescription product. Both products use ingredients derived from the Croton lechleri tree, which is sustainably harvested.
Jaguar has filed nine Investigational New Animal Drug applications with the FDA and intends to develop species-specific formulations of Neonorm in six additional target species and formulations of Canalevia for cats, horses and dogs.